{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:10:05Z","timestamp":1759453805163,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ccm.2013.08.007","type":"journal-article","created":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T16:30:38Z","timestamp":1382027438000},"page":"841-855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Combination Therapy in Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"34","author":[{"given":"Meredith E.","family":"Pugh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna R.","family":"Hemnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan M.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2013.08.007_bib1","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib2","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A\u00a0comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib6","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.08.007_bib7","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib9","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.08.007_bib10","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccm.2013.08.007_bib11","doi-asserted-by":"crossref","first-page":"L1361","DOI":"10.1152\/ajplung.2001.281.6.L1361","article-title":"Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension","volume":"281","author":"Schermuly","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.08.007_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/01902140490266475","article-title":"Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol","volume":"30","author":"Kuhn","year":"2004","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.ccm.2013.08.007_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the reveal registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.08.007_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.03.00008003","article-title":"Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids","volume":"22","author":"Hoeper","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.08.007_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1378\/chest.128.2.709","article-title":"Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy","volume":"128","author":"Seyfarth","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.08.007_bib18","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jacc.2006.05.070","article-title":"Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension","volume":"48","author":"Channick","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","article-title":"Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ccm.2013.08.007_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.healun.2011.11.002","article-title":"Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study","volume":"31","author":"Kemp","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.ccm.2013.08.007_bib21","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1253\/circj.72.1142","article-title":"Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol","volume":"72","author":"Akagi","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.ccm.2013.08.007_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1378\/chest.07-2111","article-title":"Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan","volume":"134","author":"Benza","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.08.007_bib23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2010.06.064","article-title":"Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings","volume":"106","author":"Ivy","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.08.007_bib25","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.08.007_bib27","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib28","first-page":"946","article-title":"Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results","volume":"57","author":"Jimenez Lopez-Guarch","year":"2004","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.healun.2006.09.016","article-title":"Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience","volume":"25","author":"Ruiz","year":"2006","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.ccm.2013.08.007_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","article-title":"Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension","volume":"42","author":"Ghofrani","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib31","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.amjcard.2005.06.083","article-title":"Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension","volume":"96","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1253\/circj.69.461","article-title":"Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol","volume":"69","author":"Kataoka","year":"2005","journal-title":"Circ J"},{"key":"10.1016\/j.ccm.2013.08.007_bib33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib34","first-page":"947","article-title":"Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States","volume":"15","author":"Copher","year":"2012","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ccm.2013.08.007_bib35","first-page":"393","article-title":"Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States","volume":"13","author":"Angalakuditi","year":"2010","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ccm.2013.08.007_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","article-title":"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension","volume":"60","author":"Paul","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ccm.2013.08.007_bib37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects","volume":"48","author":"Wrishko","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ccm.2013.08.007_bib38","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1002\/jps.21789","article-title":"No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers","volume":"98","author":"Spence","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.ccm.2013.08.007_bib39","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0091270009341182","article-title":"Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study","volume":"49","author":"Gruenig","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ccm.2013.08.007_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1183\/09031936.00081706","article-title":"Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension","volume":"29","author":"Mathai","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.08.007_bib41","first-page":"427","article-title":"Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy","volume":"15","author":"Porhownik","year":"2008","journal-title":"Can Respir J"},{"key":"10.1016\/j.ccm.2013.08.007_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1445-5994.2010.02403.x","article-title":"Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report","volume":"41","author":"Keogh","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.ccm.2013.08.007_bib43","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","article-title":"Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension","volume":"24","author":"Hoeper","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.08.007_bib44","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/01.smj.0000217927.81107.65","article-title":"Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan","volume":"99","author":"Minai","year":"2006","journal-title":"South Med J"},{"key":"10.1016\/j.ccm.2013.08.007_bib45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/kep398","article-title":"Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil","volume":"49","author":"Launay","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 3","key":"10.1016\/j.ccm.2013.08.007_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2362.2006.01692.x","article-title":"First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension","volume":"36","author":"Lunze","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ccm.2013.08.007_bib47","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2010.10.051","article-title":"Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology","volume":"155","author":"D'Alto","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib48","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccm.2013.08.007_bib49","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.ccm.2013.08.007_bib50","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib51","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.007_bib52","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.08.007_bib53","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.08.007_bib54","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1378\/chest.126.3.808","article-title":"Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension","volume":"126","author":"Suleman","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.08.007_bib55","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1378\/chest.130.5.1471","article-title":"Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study","volume":"130","author":"Steiner","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.08.007_bib56","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.rmed.2009.05.009","article-title":"Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan","volume":"103","author":"Safdar","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib57","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.amjcard.2003.12.031","article-title":"Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan","volume":"93","author":"Ivy","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccm.2013.08.007_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.healun.2007.01.022","article-title":"Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension","volume":"26","author":"Johnson","year":"2007","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.ccm.2013.08.007_bib59","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.healun.2007.07.040","article-title":"Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension","volume":"26","author":"Keogh","year":"2007","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.ccm.2013.08.007_bib60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.rmed.2007.12.020","article-title":"Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension","volume":"102","author":"Diaz-Guzman","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2013.08.007_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000334431","article-title":"Combination therapy in pulmonary arterial hypertension: a meta-analysis","volume":"120","author":"Bai","year":"2011","journal-title":"Cardiology"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027252311300107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027252311300107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:50:01Z","timestamp":1759452601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027252311300107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S027252311300107X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2013.08.007","relation":{},"ISSN":["0272-5231"],"issn-type":[{"type":"print","value":"0272-5231"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Therapy in Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2013.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}